MedTrace Logo

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

NCT01202513 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-08-03

No results posted yet for this study

Summary

Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments.

There are no clinical studies of use of Bimatoprost in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues; hence, the investigators decided to use it in treatment of localized vitiligo.

Conditions

  • Vitiligo
  • Repigmentation

Interventions

DRUG

Bimatoprost 0.03% topical ophthalmic solution

Sponsors & Collaborators

  • Gian Sagar Medical College and Hospital

    lead OTHER

Principal Investigators

  • Rajeev Jain, M.D. · PP

  • Tarun Narang, MD · GSMCH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2010-11-30
Completion
2010-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01202513 on ClinicalTrials.gov